

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO Box 1430 Alexandria, Virginia 22313-1450 www.tepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/574,910	02/14/2007	Chikashi Nakamura	8156/88120	7124	
42798 FITCH EVEN	7590 04/13/2009 I, TABIN & FLANNERY	EXAM	EXAMINER		
P. O. BOX 18-	415		CORDERO GARCIA, MARCELA M  ART UNIT PAPER NUMBER		
WASHINGTO	N, DC 20036				
			1654		
			MAIL DATE	DELIVERY MODE	
			04/13/2009	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Office Action Summary

Application No.	Applicant(s)			
10/574,910	NAKAMURA ET AL.			
Examiner	Art Unit			
MARCELA M. CORDERO GARCIA	1654			

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS.

- WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.
- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.

<ul> <li>Failure t Any repl</li> </ul>	end of regy is specined above, the miximum statutory period will apply and will expire stu (e) MUNI His rom the maining date of mix communication, to regly within the size of extended period for reply with, by testulate, cause the application to bocome ABANDONED (SU.S.C.) \$ 133). by received by the Office later than three months after the mailing date of this communication, even if timely filled, may reduce any patient term adjustment. See 37 OFT 1.704(b).
Status	
2a)□ T 3)□ S	Responsive to communication(s) filed on  This action is FINAL. 2b) This action is non-final.  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is losed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.
Disposition	n of Claims
4a 5)□ C 6)□ C 7)□ C	claim(s) <u>1-16</u> is/are pending in the application.  a) Of the above claim(s) is/are withdrawn from consideration.  claim(s) is/are allowed.  claim(s) is/are rejected.  claim(s) is/are objected to.  claim(s) <u>1-16</u> are subject to restriction and/or election requirement.
Application	n Papers
10)☐ Th Al R	ne specification is objected to by the Examiner.  ne drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  pplicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  teplacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d) are oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.
Priority un	der 35 U.S.C. § 119
a) 1. 2. 3.	cknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).   All b  Some * c)  None of:

Attachment(s)

1)	Ш	Notice	of	References	Cited	(PT	D-892)		
2)		Motico	Λf	Draftenorea	n'e Da	tont	Drawing	Poviour	/D

 Notice of Draftsperson's Patent Drawing Review (PTO-948)
 Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date \_\_\_\_\_

4) Interview Summary (PTO-413) Paper No(s)/Mail Date. \_\_\_\_\_. 5) Notice of Informal Patent Application

6) Other: .

Application/Control Number: 10/574,910 Page 2

Art Unit: 1654

## DETAILED ACTION

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-10, 12-13, drawn to an oligopeptide represented by Formula II
   A<sub>1</sub>-Leu-Asp-Gln-A<sub>2</sub>-(X)<sub>n</sub>, classified, e.g., in class 530, subclass 300.
- Claims 11 and 14-15, drawn to a method of detecting or quantifying dioxin, classified, e.g., in class 436, subclass 501.
- III. Claim 16, drawn to a method of extracting dioxin, classified, e.g., in class 436, subclass 518.

The inventions are distinct, each from the other because of the following reasons: Inventions II and III are directed to related methods. The related inventions are distinct if: (1) the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect; (2) the inventions do not overlap in scope, i.e., are mutually exclusive; and (3) the inventions as claimed are not obvious variants. See MPEP § 806.05(j). In the instant case, the inventions as claimed are drawn to a method of detecting or quantifying dioxin and to a method of extracting dioxin. Furthermore, the inventions as claimed do not encompass overlapping subject matter and there is nothing of record to show them to be obvious variants.

Inventions I and II-III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the

Art Unit: 1654

process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case, the oligopeptides of the instant invention may also be used in the determination of fragmentation patterns in mass spectrometric methods.

Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

- (a) the inventions have acquired a separate status in the art in view of their different classification;
- (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;
- (c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);
- (d) the prior art applicable to one invention would not likely be applicable to another invention;
- (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a invention to be examined even though the requirement

Art Unit: 1654

may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

This application contains claims directed to the following patentably distinct specie: the many and multiple peptides of formula A<sub>1</sub>-Leu-Asp-Gln-A<sub>2</sub>-(X)<sub>n</sub>; the many and multiple labeled dummies in the method of detecting or quantifying dioxin. The species are independent or distinct because claims to the different species recite the

Art Unit: 1654

mutually exclusive characteristics of such species. In addition, these species are not obvious variants of each other based on the current record.

In addition, Applicant is required under 35 U.S.C. 121 to elect a single disclosed species [i.e., elect a single and specific oligopeptide with all the substituents: A<sub>1</sub>, A<sub>2</sub> and X<sub>n</sub> fully assigned. If Group II is elected, please also elect a labeled dummy compound as well] for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-16 are generic.

There is an examination and search burden for these patentably distinct species due to their mutually exclusive characteristics. The species require a different field of search (e.g., searching different classes/subclasses or electronic resources, or employing different search queries); and/or the prior art applicable to one species would not likely be applicable to another species; and/or the species are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

The election of the species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the election of species requirement, the

Art Unit: 1654

election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected species.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other species.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise

Art Unit: 1654

require all the limitations of the allowable product claim will be considered for rejoinder.

<u>All</u> claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCELA M. CORDERO GARCIA whose telephone number is (571)272-2939. The examiner can normally be reached on M-F 8:30-5:00.

Art Unit: 1654

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia J. Tsang can be reached on (571) 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Anish Gupta/ Primary Examiner, Art Unit 1654 /Marcela M Cordero Garcia/ Examiner, Art Unit 1654

MMCG 04/09